share_log

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga Real-time News ·  Dec 26, 2022 08:08

Gainers

  • Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday's pre-market session. The market value of their outstanding shares is at $13.0 million.
  • DBV Technologies (NASDAQ:DBVT) shares moved upwards by 27.11% to $1.5. The company's market cap stands at $281.9 million.
  • Humanigen (NASDAQ:HGEN) shares rose 18.09% to $0.12. The company's market cap stands at $14.1 million.
  • Owlet (NYSE:OWLT) stock moved upwards by 13.28% to $0.82. The market value of their outstanding shares is at $93.8 million.
  • NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 13.06% to $0.24. The company's market cap stands at $7.9 million. The company's, Q4 earnings came out 3 days ago.
  • Personalis (NASDAQ:PSNL) shares moved upwards by 12.9% to $2.1. The company's market cap stands at $96.5 million.

Losers

  • Applied Molecular (NASDAQ:AMTI) stock decreased by 27.2% to $0.75 during Monday's pre-market session. The market value of their outstanding shares is at $29.2 million.
  • Otonomy (NASDAQ:OTIC) stock declined by 22.08% to $0.06. The market value of their outstanding shares is at $3.4 million.
  • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares declined by 18.61% to $1.05. The market value of their outstanding shares is at $6.8 million.
  • Athenex (NASDAQ:ATNX) stock fell 11.01% to $0.15. The market value of their outstanding shares is at $23.6 million.
  • Satsuma Pharmaceuticals (NASDAQ:STSA) stock declined by 9.38% to $0.76. The market value of their outstanding shares is at $25.3 million.
  • Aytu BioPharma (NASDAQ:AYTU) stock fell 8.73% to $0.19. The company's market cap stands at $11.9 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment